B族链球菌：全球发病率与疫苗研发
Group B Streptococcus: global incidence and vaccine development.
作者信息
Johri Atul Kumar, Paoletti Lawrence C, Glaser Philippe, Dua Meenakshi, Sharma Puja Kumari, Grandi Guido, Rappuoli Rino
机构信息
School of Life Sciences, Jawaharlal Nehru University, New Delhi 110067, India.
出版信息
Nat Rev Microbiol. 2006 Dec;4(12):932-42. doi: 10.1038/nrmicro1552. Epub 2006 Nov 6.
Abstract
An ongoing public health challenge is to develop vaccines that are effective against infectious diseases that have global relevance. Vaccines against serotypes of group B Streptococcus (GBS) that are prevalent in the United States and Europe are not optimally efficacious against serotypes common to other parts of the world. New technologies and innovative approaches are being used to identify GBS antigens that overcome serotype-specificity and that could form the basis of a globally effective vaccine against this opportunistic pathogen. This Review highlights efforts towards this goal and describes a template that can be followed to develop vaccines against other bacterial pathogens.
摘要
一项持续存在的公共卫生挑战是研发出对具有全球影响的传染病有效的疫苗。针对在美国和欧洲流行的B族链球菌（GBS）血清型的疫苗，对世界其他地区常见的血清型的效果并不理想。新技术和创新方法正被用于识别GBS抗原，这些抗原可克服血清型特异性，并可能成为针对这种机会性病原体的全球有效疫苗的基础。本综述重点介绍了为实现这一目标所做的努力，并描述了一种可遵循的模板，用于研发针对其他细菌病原体的疫苗。
相似文献
1
Group B Streptococcus: global incidence and vaccine development.
Nat Rev Microbiol. 2006 Dec;4(12):932-42. doi: 10.1038/nrmicro1552. Epub 2006 Nov 6.
2
Surface Structures of Group B Important in Human Immunity.
Microbiol Spectr. 2019 Mar;7(2). doi: 10.1128/microbiolspec.GPP3-0001-2017.
3
Alpha C protein as a carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal vaccines.
Infect Immun. 1999 May;67(5):2491-6. doi: 10.1128/IAI.67.5.2491-2496.1999.
4
Prevention of systemic infections caused by group B streptococcus and Staphylococcus aureus by multivalent polysaccharide-protein conjugate vaccines.
Ann N Y Acad Sci. 1995 May 31;754:68-82. doi: 10.1111/j.1749-6632.1995.tb44439.x.
5
The soluble antigens of GBS as human vaccines.
Antibiot Chemother (1971). 1985;35:291-5. doi: 10.1159/000410382.
6
Capsular switching in group B Streptococcus CC17 hypervirulent clone: a future challenge for polysaccharide vaccine development.
J Infect Dis. 2012 Dec 1;206(11):1745-52. doi: 10.1093/infdis/jis605. Epub 2012 Sep 21.
7
Group B streptococcus and early-onset sepsis in the era of maternal prophylaxis.
Pediatr Clin North Am. 2009 Jun;56(3):689-708, Table of Contents. doi: 10.1016/j.pcl.2009.04.003.
8
Natural acquired humoral immunity against serotype-specific group B Streptococcus rectovaginal colonization acquisition in pregnant women.
Clin Microbiol Infect. 2015 Jun;21(6):568.e13-21. doi: 10.1016/j.cmi.2015.01.030. Epub 2015 Feb 10.
9
Vaccine prevention of group B streptococcal disease.
Pediatr Ann. 1993 Dec;22(12):711-4. doi: 10.3928/0090-4481-19931201-05.
10
Maternal group B streptococcal immunization: capsular polysaccharide (CPS)-based vaccines and their implications on prevention.
Vaccine. 2011 May 12;29(21):3729-30. doi: 10.1016/j.vaccine.2011.02.102. Epub 2011 Mar 15.
引用本文的文献
1
Harnessing subtractive genomics for drug target identification in Streptococcus agalactiae serotype v (atcc baa-611 / 2603 v/r) strain: An in-silico approach.
PLoS One. 2025 Aug 21;20(8):e0319368. doi: 10.1371/journal.pone.0319368. eCollection 2025.
2
The challenge of antimicrobial resistance in the Asia-Pacific: a pediatric perspective.
Curr Opin Pediatr. 2025 Apr 1;37(2):116-123. doi: 10.1097/MOP.0000000000001437. Epub 2025 Feb 4.
3
Pathogenic characterization and drug resistance of neonatal sepsis in China: a systematic review and meta-analysis.
Eur J Clin Microbiol Infect Dis. 2025 Apr;44(4):779-788. doi: 10.1007/s10096-025-05048-1. Epub 2025 Jan 24.
4
Structural and functional analysis reveals the catalytic mechanism and substrate binding mode of the broad-spectrum endolysin Ply2741.
Virulence. 2025 Dec;16(1):2449025. doi: 10.1080/21505594.2024.2449025. Epub 2025 Jan 14.
5
Infection in Wild Trahira () and Farmed Arapaima () in Brazil: An Interspecies Transmission in Aquatic Environments Shared with Nile Tilapia ().
Microorganisms. 2024 Nov 22;12(12):2393. doi: 10.3390/microorganisms12122393.
6
Exploiting the Zebrafish Model for Sepsis Research: Insights into Pathophysiology and Therapeutic Potentials.
Drug Des Devel Ther. 2024 Nov 22;18:5333-5349. doi: 10.2147/DDDT.S500276. eCollection 2024.
7
A novel chimeric endolysin Cly2v shows potential in treating streptococci-induced bovine mastitis and systemic infections.
Front Microbiol. 2024 Oct 18;15:1482189. doi: 10.3389/fmicb.2024.1482189. eCollection 2024.
8
Isolation and characterization of Streptococcus agalactiae inducing mass mortalities in cultured Nile tilapia (Oreochromis niloticus) with trials for disease control using zinc oxide nanoparticles and ethanolic leaf extracts of some medicinal plants.
BMC Vet Res. 2024 Oct 15;20(1):468. doi: 10.1186/s12917-024-04298-z.
9
Group B streptococcus colonization in pregnancy and neonatal outcomes: a three-year monocentric retrospective study during and after the COVID-19 pandemic.
Ital J Pediatr. 2024 Sep 13;50(1):175. doi: 10.1186/s13052-024-01738-2.
10
Unmutated but T cell dependent IgM antibodies targeting Streptococcus suis play an essential role in bacterial clearance.
PLoS Pathog. 2024 Jan 19;20(1):e1011957. doi: 10.1371/journal.ppat.1011957. eCollection 2024 Jan.
本文引用的文献
1
TWO SEROLOGICAL TYPES OF GROUP B HEMOLYTIC STREPTOCOCCI WITH RELATED, BUT NOT IDENTICAL, TYPE-SPECIFIC SUBSTANCES.
J Exp Med. 1938 Jan 1;67(1):25-40. doi: 10.1084/jem.67.1.25.
2
A SEROLOGICAL DIFFERENTIATION OF SPECIFIC TYPES OF BOVINE HEMOLYTIC STREPTOCOCCI (GROUP B).
J Exp Med. 1934 Mar 31;59(4):441-58. doi: 10.1084/jem.59.4.441.
3
Use of Lactococcus lactis expressing pili from group B Streptococcus as a broad-coverage vaccine against streptococcal disease.
J Infect Dis. 2006 Aug 1;194(3):331-40. doi: 10.1086/505433. Epub 2006 Jun 30.
4
Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae.
Mol Microbiol. 2006 Jul;61(1):126-41. doi: 10.1111/j.1365-2958.2006.05225.x.
5
Assembly and role of pili in group B streptococci.
Mol Microbiol. 2006 Jun;60(6):1401-13. doi: 10.1111/j.1365-2958.2006.05190.x.
6
Pili in gram-positive pathogens.
Nat Rev Microbiol. 2006 Jul;4(7):509-19. doi: 10.1038/nrmicro1443.
7
Post-genomic vaccine development.
FEBS Lett. 2006 May 22;580(12):2985-92. doi: 10.1016/j.febslet.2006.04.084. Epub 2006 May 4.
8
Genomic diversity and evolution within the species Streptococcus agalactiae.
Microbes Infect. 2006 Apr;8(5):1227-43. doi: 10.1016/j.micinf.2005.11.010. Epub 2006 Jan 19.
9
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial "pan-genome".
Proc Natl Acad Sci U S A. 2005 Sep 27;102(39):13950-5. doi: 10.1073/pnas.0506758102. Epub 2005 Sep 19.
10
Group B streptococcal infections in elderly adults.
Clin Infect Dis. 2005 Sep 15;41(6):839-47. doi: 10.1086/432804. Epub 2005 Aug 16.
Zotero 插件